NCT07854886Recruiting
Hypothalamic GLP-1 Response in Healthy Weight and Obesity
Quantifying Hypothalamic GLP-1 Response in Healthy Weight and Obesity: A Randomized Crossover Neuroimaging Infusion Study
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn how the gut hormone glucagon-like peptide-1 (GLP-1) helps the brain sense sugar. It includes adults with healthy weight and adults with obesity. The main questions this trial aims to answer are: A. Does GLP-1 cause the brain's response to sugar? B. Do lower GLP-1 levels cause a weaker brain response to sugar in adults with obesity? Researchers will compare each participant's brain response across four test days. On these days, GLP-1 levels will be blocked, raised, or left unchanged. Sugar will be given either into the stomach or into a vein. Participants will: Attend 1 screening visit Visit the clinic for 4 test days Receive sugar and get an MRI scan of their brain on each test day
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 17 Sept 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- University of Copenhagen
- Diseases
- Obesity
- NCT number
- NCT07854886
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 1 Oct 2026 to the primary completion date, 30 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with GLP-1 receptor agonists or other GLP-1-based therapies within the past three months
- Previous bariatric surgery
- Women using hormonal contraception (oral contraceptives, progestin- containing implants or hormonal intrauterine device.)
Other illness
- Current eating disorder (anorexia nervosa, bulimia nervosa)
- Contraindications to study procedures, including:
- Esophageal or nasal obstruction (e.g. tumors, strictures)
- Coagulopathy
- History of skull base trauma
- Esophageal varices
- Hiatal hernia
- Claustrophobia
- Inability to comply with MRI requirements (e.g. remaining still)
- Presence of non-removable magnetic objects incompatible with MRI
- Any other condition or circumstance that, in the opinion of the study physician, may compromise safe participation in the study.
Lab values
- Diabetes mellitus type 1 or type 2, or fasting plasma glucose \> 7.0 mmol/L
- Use of medication affecting appetite, body weight, or glucose metabolism within the past three months
- Known serious chronic disease, including but not limited to:
- Heart disease
- Anemia (hemoglobin \<7.0 mmol/L for women, \<8.0 mmol/L for men)
- Renal impairment (eGFR \<60 mL/min/1.73m²)
- Hepatic impairment (ALT or AST \>3 times upper limit of normal)
Other
- Known monogenic obesity
- Substance abuse (current or within the past year)
- Pregnancy, breastfeeding, or wish to become pregnant during the study period
- Women of childbearing potential not using adequate contraception
Who the study is looking for
- Group 1:
- Age 18-75 years
- BMI 18.5-25 kg/m²
- Normal glucose tolerance (Fasting glucose \< 5.6 mmol/L)
- Group 2:
- Age and sex-matched with group 1
- BMI≥30 kg/m²
- Impaired glucose tolerance (Fasting glucose 5.6 - 6.9 mmol/L)
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Copenhagen, Department of Biomedical Sciences Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.